DUXAP8 and lung adenocarcinoma: Moreover, The Cancer Genome Atlas (TCGA) database showed that DUXAP8 in lung adenocarcinoma patients (LUAD) was significantly higher than in noncancerous tissue, and the level of DUXAP8 upregulation was associated with poor prognosis and reduced survival (Figures 4E, F).